Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.74 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.74 |
| ▸ | MAPT | P10636 | 2/20 | 0.74 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.74 |
| ▸ | TSHR | P16473 | 1/20 | 0.74 |
| ▸ | BLM | P54132 | 1/20 | 0.74 |
| ▸ | AGER | Q15109 | 1/20 | 0.74 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.74 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.74 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | NAPRT | Q6XQN6 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | MYC | P01106 | 2/20 | 0.50 |
| ▸ | DHODH | Q02127 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9630450 | 0.98 | ALDH1A1 (0.71) | ALDH1A1KDM4EMAPTALOX15CYP3A4 | |
| Quinolinic Acid SCHEMBL125075 | 0.88 | KDM4E (0.88) | ALDH1A1KDM4EMAPTALOX15CYP3A4 | |
| SCHEMBL187727 | 0.88 | KDM4E (0.55) | ALDH1A1KDM4EMAPTALOX15CYP3A4 | |
| Quinolinic Acid SCHEMBL27676801 | 0.85 | KDM4E (1.00) | ALDH1A1KDM4EMAPTALOX15CYP3A4 | |
| Quinolinic Acid SCHEMBL69230 | 0.85 | KDM4E (1.00) | ALDH1A1KDM4EMAPTALOX15CYP3A4 | |
| Quinolinic Acid SCHEMBL343618 | 0.85 | KDM4E (1.00) | ALDH1A1KDM4EMAPTALOX15CYP3A4 | |
| Quinolinic Acid SCHEMBL29356188 | 0.85 | KDM4E (1.00) | ALDH1A1KDM4EMAPTALOX15CYP3A4 | |
| Quinolinic Acid SCHEMBL27862037 | 0.84 | KDM4E (0.88) | ALDH1A1KDM4EMAPTALOX15CYP3A4 | |
| SCHEMBL3006650 | 0.84 | KDM4E (0.74) | ALDH1A1KDM4EMAPTALOX15CYP3A4 | |
| Quinolinic Acid SCHEMBL3744925 | 0.83 | KDM4E (0.96) | ALDH1A1KDM4EMAPTALOX15CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007053773-A1 | COMPOSITIONS AND METHODS USING NICOTINIC ACID FOR TREATMENT OF HYPERCHOLESTEROLEMIA, HYPERLIPIDEMIA AND CARDIOVASCULAR DISEASE | HENDRIX CURT (US) | 2007-05-10 | — | — | WO | claimed |
| US-20070105793-A1 | Compositions and methods using nicotinic acid for treatment of hypercholesterolemia, hyperlipidemia nd cardiovascular disease | CONCOURSE HEALTH SCIENCES LLC | 2007-05-10 | — | — | US | claimed |
| EP-0219451-B1 | SEMICARBAZONES AND THIOSEMICARBAZONES | SANDOZ AG (CH) | 1991-03-20 | — | — | EP | claimed |
| CN-119751349-A | Method for continuously synthesizing 8-methylquinoline | 江苏优士化学有限公司 | 2025-04-04 | — | — | CN | disclosed |
| US-20230219937-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | SANOFI (FR) | 2023-07-13 | — | — | US | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-9388175-B2 | 2-aniline-4-aryl substituted thiazole derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2016-07-12 | — | — | US | disclosed |
| US-20150246958-A1 | BIOREVERSABLE PROMOIETIES FOR NITROGEN-CONTAINING AND HYDROXYL-CONTAINING DRUGS | BAIKANG (SUZHOU) CO., LTD (CN) | 2015-09-03 | — | — | US | disclosed |
| US-20110269748-A1 | 2-ANILINE-4-ARYL SUBSTITUTED THIAZOLE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-11-03 | — | — | US | disclosed |
| EP-2272510-A1 | Inhibitors of the proline racemase of trypanosoma cruzi | Institut Pasteur (FR) | 2011-01-12 | — | — | EP | disclosed |
| US-7645771-B2 | CCR5 antagonists as therapeutic agents | SMITHKLINE BEECHAM CORP. (US) | 2010-01-12 | — | — | US | disclosed |
| US-5665674-A | SEMICARBAZONES | SANDOZ LTD. (CH) | 1997-09-09 | — | — | US | disclosed |
| WO-1997003051-A1 | PROCESS FOR PREPARING QUINOLINE BASES | REILLY INDUSTRIES, INC. (US) | 1997-01-30 | — | — | WO | disclosed |
| EP-0739341-A1 | HERBICIDAL ARYL AND HETEROARYL PYRIMIDINES | Novartis AG (CH) | 1996-10-30 | — | — | EP | disclosed |
| US-5506191-A | Heterocyclic hydrazines and hydrazones | SANDOZ LTD. (CH) | 1996-04-09 | — | — | US | disclosed |
| WO-1995019358-A1 | HERBICIDAL ARYL AND HETEROARYL PYRIMIDINES | SANDOZ LTD. (CH) | 1995-07-20 | — | — | WO | disclosed |
| US-5098462-A | Herbicides | SANDOZ LTD. (CH) | 1992-03-24 | — | — | US | disclosed |
| US-5098466-A | Herbicides | SANDOZ LTD. (CH) | 1992-03-24 | — | — | US | disclosed |
| EP-0219451-B1 | SEMICARBAZONES AND THIOSEMICARBAZONES | SANDOZ AG (CH) | 1991-03-20 | — | — | EP | disclosed |
| EP-0219451-A1 | Semicarbazones and thiosemicarbazones | SANDOZ AG (CH) | 1987-04-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269748-A1 | 2-ANILINE-4-ARYL SUBSTITUTED THIAZOLE DERIVATIVES | CHRNA4, CHRNA5, CHRNA7 | ALDH1A1 582/4885KDM4E 3173/4885MAPT 3954/4885 |
| US-20150246958-A1 | BIOREVERSABLE PROMOIETIES FOR NITROGEN-CONTAINING AND HYDROXYL-CONTAINING DRUGS | NOS2, EGLN2, HPGD | ALDH1A1 234/4885KDM4E 1589/4885MAPT 3377/4885 |
| US-20230219937-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | RIPK1, RIPK4, RIPK2 | ALDH1A1 2211/4885KDM4E 2270/4885MAPT 3860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.